MedTrace Logo

Pharmacokinetics and Bioavailability of Curcumin UP 30 Capsules in Healthy Adult Subjects

NCT05334043 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-04-19

No results posted yet for this study

Summary

A single-center, open-label, randomized, two-period, crossover study design of pharmacokinetics and bioavailability in healthy adult male and female subjects under fasting conditions.

Conditions

  • Healthy Adult Subjects

Interventions

DRUG

CuminUP30

7 capsules, 500 mg / capsule

DRUG

Curcumin capsules

5 capsules, 450 mg / capsule

Sponsors & Collaborators

  • Chenland Nutritionals Inc.

    collaborator INDUSTRY

  • The Affiliated Hospital of Qingdao University

    lead OTHER

Principal Investigators

  • Yu Cao · Qingdao University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-23
Primary Completion
2022-04-07
Completion
2022-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05334043 on ClinicalTrials.gov